BQB1 Stock Overview
Yourgene Health Plc, a molecular diagnostic company, researches, develops, and commercializes gene analysis techniques for prenatal screening and other applications in the United Kingdom, rest of Europe, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Yourgene Health Plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.001 |
| 52 Week High | UK£0.067 |
| 52 Week Low | UK£0.0005 |
| Beta | 0.86 |
| 1 Month Change | -66.67% |
| 3 Month Change | 100.00% |
| 1 Year Change | -98.29% |
| 3 Year Change | -99.44% |
| 5 Year Change | -99.25% |
| Change since IPO | -98.85% |
Recent News & Updates
Recent updates
Shareholder Returns
| BQB1 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 0% | 2.6% | 1.2% |
| 1Y | -98.3% | -8.3% | 2.0% |
Return vs Industry: BQB1 underperformed the German Medical Equipment industry which returned -2.5% over the past year.
Return vs Market: BQB1 underperformed the German Market which returned 5.9% over the past year.
Price Volatility
| BQB1 volatility | |
|---|---|
| BQB1 Average Weekly Movement | 142.1% |
| Medical Equipment Industry Average Movement | 4.7% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.1% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: BQB1's share price has been volatile over the past 3 months.
Volatility Over Time: BQB1's weekly volatility has increased from 123% to 142% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 253 | Lyn Rees | www.yourgene-health.com |
Yourgene Health Plc, a molecular diagnostic company, researches, develops, and commercializes gene analysis techniques for prenatal screening and other applications in the United Kingdom, rest of Europe, and internationally. It develops in vitro diagnostic products, such as IONA Test, a non-invasive pre-natal test (NIPT) for Down’s syndrome, Edwards' syndrome, and Patau’s Syndrome in pregnant women; Cystic Fibrosis Screening tests; Rapid Aneuploidy Analysis, a confirmatory diagnostic test carried out after amniocentesi; and Recurrent Pregnancy Loss, a PCR assay for the routine diagnosis of the six most common chromosomes related to pregnancy loss, as well as DPYD genotyping products. The company also offers Ranger, a technology platform for sample size selection and enrichment; Elucigene DPYD assay, a PCR test to predict a patient’s response to a chemotherapy treatment; and Clarigene SARS-CoV-2 CE-IVD, a PCR assay used for routine COVID-19 testing.
Yourgene Health Plc Fundamentals Summary
| BQB1 fundamental statistics | |
|---|---|
| Market cap | €19.15m |
| Earnings (TTM) | -€9.52m |
| Revenue (TTM) | €34.54m |
0.6x
P/S Ratio-2.0x
P/E RatioIs BQB1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BQB1 income statement (TTM) | |
|---|---|
| Revenue | UK£29.67m |
| Cost of Revenue | UK£13.21m |
| Gross Profit | UK£16.46m |
| Other Expenses | UK£24.63m |
| Earnings | -UK£8.17m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0026 |
| Gross Margin | 55.48% |
| Net Profit Margin | -27.55% |
| Debt/Equity Ratio | 15.7% |
How did BQB1 perform over the long term?
See historical performance and comparison